|Basic InformationMore InformationTestsLatest News|Antidepressants Used by 12.7 Percent of Those Age ≥12 in U.S.U.S. Antidepressant Use Jumps 65 Percent in 15 YearsSmoking During Pregnancy Up Among Women With DepressionDepression After Coronary Artery Disease Diagnosis Ups Death RiskYoga May Help Ease DepressionLonger Estrogen Exposure May Protect Against DepressionEstrogen May Influence Women's Depression RiskLosing Medicaid Tough on People Battling Depression: StudyAddition of Aripiprazole Ups Major Depressive Disorder RemissionNo Sign That Antidepressants in Pregnancy Harm Kids' Brains: StudyMed Switch Not Always Best Choice With Tough DepressionDepression Contributes to Health Decline Seen in Cancer CaregiversDepression May Worsen Health for Cancer CaregiversElectric Brain Stimulation No Better Than Meds For Depression: StudyDepression Inversely Linked to Body Composition in TeensReview: Depression Screening As Inpatient Important, FeasibleDepression Can Slow Hospital Patients' Recovery: StudyAntidepressants During Pregnancy Safe for Baby: StudyWhat You Need to Know About AntidepressantsAPA: Internet-Based CBT Can Be Helpful in DepressionCan Online Treatment Replace Your Therapist?Depression Often a Precursor to Falls in Elderly PeopleObesity, Sex Predict Remission for Antidepressant MedicationsGender Differences in Depression Tend to Appear About Age 12Depression's Gender Gap Shows Up in Pre-Teen YearsStudies Question Link Between Mom's Antidepressant Use, Autism in KidsTrauma as a Teen May Boost Depression Risk Around MenopauseBlood Test Promising for ID of Early Depression, SchizophreniaBlood Test Might Someday Distinguish Early Depression, SchizophreniaHold That Pose: Yoga May Ease Tough DepressionDepression May Hasten Death in Years After Heart DiagnosisAntidepressant Efficacy Varies for Depressive Symptom ClustersDepressed Psoriasis Patients at Higher Risk of Psoriatic ArthritisCan Depression Up Odds for Arthritis Linked to Psoriasis?Postpartum Depressive Symptoms Fell in 2004 to 2012Depression Often Untreated in Dialysis PatientsPostpartum Depression Affects New Dads, TooPanic Disorder May Up Odds of Depression Rx Side EffectsSometimes the Holidays Aren't Always JollyPilots Suffer Depression, Suicidal Thoughts at Fairly High RatesMore Than 1 in 10 Pilots Suffer From Depression, Survey FindsSelf-Care Tools Cut Depression in AMD, Diabetic RetinopathyDepression, Suicide Ideation Prevalent in Medical StudentsDepression on the Rise Among U.S. Teens, Especially GirlsDepressive Symptoms Linked to Functional Status in CADHigh Rate of Antidepressant Use After CancerResearchers Find Antidepressant Bupropion Crosses PlacentaMom-to-Be's Antidepressant Use May Be Tied to Speech Issues in ChildDepression Can Fuel Heart Disease in Midlife Women: StudyDepression Common in Patients With Chronic AnginaQuestions and AnswersVideosLinksBook Reviews
Obesity, Sex Predict Remission for Antidepressant Medications
Updated: May 4th 2017
THURSDAY, May 4, 2017 (HealthDay News) -- Obesity and sex are differential predictors of acute remission for commonly used antidepressant medications, according to a study published in the March-April issue of Personalized Medicine in Psychiatry.
Erin Green, Ph.D., from the VA Palo Alto Health Care System in California, and colleagues obtained data for 659 outpatients (ages 18 to 65 years) who completed the iSPOT-D practical randomized controlled trial. The patients were classified as normal-weight, overweight, or obese, based on World Health Organization criteria (42, 28, and 31 percent, respectively). Participants were randomized to eight weeks of escitalopram, sertraline, or venlafaxine extended-release (venlafaxine-XR) and were then categorized as remitters or non-remitters.
The researchers found that body mass index (BMI) was a differential predictor of remission based on antidepressant type. Compared with normal-weight patients, morbidly obese patients were more likely to remit on venlafaxine-XR; the effect was driven by a decline in physical symptoms, including sleep disturbance, somatic anxiety, and appetite. To achieve remission with venlafaxine-XR in obese III participants, the number needed to treat was six. Females, but not males, with higher BMI were more likely to remit, irrespective of medication type; the effect correlated with change in cognitive symptoms, including suicidal ideation, guilt, and psychomotor changes.
"Our findings suggest that considering BMI and sex, and assessing specific symptoms, could help tailor antidepressant choices to improve remission from depression in specialty and primary care settings," the authors write.
Two authors disclosed financial ties to the biopharmaceutical industry; one author disclosed ties to the health insurance industry and to Brain Resource Ltd., which supported iSPOT-D.
This article: Copyright © 2017 HealthDay. All rights reserved.